An Open-label, Multi-cohort, Multi-center Phase I Study Evaluating the Efficacy and Safety of MGD013 in Patients With Unresectable, Recurrent or Metastatic Malignant Melanoma
Latest Information Update: 23 May 2023
At a glance
- Drugs Tebotelimab (Primary)
- Indications Acral lentiginous melanoma; Malignant melanoma; Skin cancer
- Focus Therapeutic Use
- Sponsors ZAI Lab
- 19 Apr 2023 Results (data cut off Jan 19,2022, n=25) presented at the 114th Annual Meeting of the American Association for Cancer Research
- 12 Apr 2022 Status changed from active, no longer recruiting to discontinued.
- 13 Jan 2022 Planned End Date changed from 1 Aug 2022 to 31 Aug 2022.